A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

← catalyst calendar

NCT06561685 · readout ≤ 438 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

340estimated

Sites

Countries

France, Germany, Japan +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-09-19

actual

When the study began enrolling

Primary completion

Oct 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Oct 2027

estimated

The whole study's end, after follow-up

First posted

2024-08-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Metastatic Solid Tumor
Advanced Solid Tumor
Non-small Cell Lung Cancer
SMARCA4-Deficient Tumor

Interventions

Drug: LY4050784
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Nab paclitaxel

Primary outcomes

what the primary-completion date above is the date OF

Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)